Kenvue set for best day ever after $48.7 billion buyout deal from Kimberly-Clark

Shares of consumer health company Kenvue KVUE.N rise 16.28% to $16.71 in early trade

Stock set for its biggest pct. rise in a single day, if gains hold

Kimberly-Clark KMB.O says it will acquire the Tylenol maker in a deal valued at about $48.7 billion

Separately, co reports Q3 adj. EPS of 28 cents vs Wall Street estimates of 27 cents - LSEG data

KVUE's shareholders will get $21.01 per share in cash and stock, implying a 46.2% premium to the stock's last closing price

*The timing of the deal was earlier than expected, given the negative litigation and regulatory headlines around KVUE, RBC Capital Markets analyst Nik Modi says

Including session's move, stock down 22.5% YTD